Mumbai, Maharashtra, India
The need of big pharma to create well balanced portfolios, superlative performance in licensing activities is crucial; it is increasingly becoming risky and expensive to develop a new pharmaceutical entity.
Management has to decide, which projects and portfolios should be funded and how, in order to create the most value for the firm. This decision can be facilitated by taking advantage of rational financial models.
Recent advances in financial modeling allow decision makers to incorporate risks in those models and to identify risk reducing operating strategies, project and portfolio modeling as a suitable tool to demonstrate the relationship between financial value, R&D and marketing strategy, and risk.
According to Jayashri Kulkarni, Director, Healthcare Practice, Frost & Sullivan, "Given the consolidation wave sweeping the Life sciences industry, the Frost & Sullivan Life Sciences Valuation Workshop arises out of the sector's need for assessing the value of own/licensed pipelines, intellectual property, portfolios and provides a significant tool for both the supply and demand sides for valuing their intellectual property".
Through lectures, case studies and practical, computer-based exercises this course will enhance participants' understanding of value-creating R&D and business strategies. The workshop will help appreciate the advantages of financial modeling and will enable evaluation of highly uncertain cash flows, and improve decision making related to investments in life sciences.
Dr. Joachim M. Greuel, the founding and managing partner of Bioscience Valuation GmbH, and a renowned advisor to Life science companies across the globe, will be conducting the workshop. He began his professional career as head of a research team at Bayer AG, Germany. Before founding Bioscience Valuation he was investment manager at New Medical Technologies, a Swiss Venture Capital Fund. Dr. Greuel holds a MBA with a finance focus from the Wharton School of the University of Pennsylvania, USA, and is an active member of the 'American Finance Association' and of the 'Institute for Operations Research and the Management Sciences', Baltimore, USA.
This one-of-a-kind workshop to be held on March 16th at the Leela Kempinski, Mumbai from 9:00 a.m. to 6:00 p.m. will provide insights to issues such as: Evaluating a R&D Project, Evaluating and optimizing a pharma-biotech portfolio, Maximizing value from licensing agreements and issue related in valuing a technology platform. Designed for CEO's and CFO's of Life Sciences and Pharmaceutical Companies as well as Senior Managers working in the area of Research and Development, Project Management, Business Development, Venture Capitalists, Investment Bankers, Strategic planners and portfolio managers, this specialized one-day workshop, besides assisting the participants in making the right investment decisions, maximize portfolio value and minimize portfolio risk, forecast and model uncertain cash flows, will also help them to increase project value by developing optimal R&D strategies.
About Frost & Sullivan: Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for over 45 years.The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com.
Shwetha Thomas, Corporate Communications, South Asia and Middle East, Frost & Sullivan, +91 (022) 4001 3429 sthomas@frost.com
Nimisha Iyer, Corporate Communications, South Asia and Middle East, Frost & Sullivan, +91 (022) 4001 3431 niyer@frost.com
Source: Frost & Sullivan (Business Wire India)
Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.
